FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1517871387> ?p ?o ?g. }

• W1517871387 endingPage "2057" @default.
• W1517871387 startingPage "2051" @default.
• W1517871387 abstract "Abstract BACKGROUND Gemcitabine is a commonly used chemotherapeutic agent structurally and pharmacologically similar to cytarabine. Recently, instances of severe gemcitabine‐associated lung injury have been reported. Herein, investigators affiliated with the Research on Adverse Drug Events and Reports (RADAR) pharmacovigilance program evaluated clinical characteristics of gemcitabine‐associated severe acute lung injury from clinical trial reports, medical literature case reports, and spontaneous reports to the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). METHODS Clinical data were obtained by reviewing adverse event case reports for gemcitabine‐associated lung injury as reported in the medical literature and in the FDA AERS database. Upper limit estimates of ADE rate were derived from review of published clinical trials reporting gemcitabine‐associated lung injury rates of 10% or higher. RESULTS A total of 178 reports of gencitabine‐associated lung injury were identified; in AERS, there were 55 cases from clinical trials and 92 spontaneous reports. A comprehensive search revealed 31 medical literature reports. Clinical features of gemcitabine‐associated lung injury included dyspnea, fever, pulmonary infiltrate, and cough with recognition of toxicity occurring after a median duration of 48 (range, 1‐529) days after initiation of gemcitabine. The taxanes, docetaxel and paclitaxel, were frequently reported as coadministered therapies. Eleven Phase II or Phase III clinical trials with 317 patients identified gemcitabine‐associated lung injury rates of greater than 10%, with the highest rates (22% and 42%) being observed in Phase III clinical trials where Hodgkin disease patients were treated with a regimen that included gemcitabine and bleomycin. CONCLUSIONS High rates of gemcitabine‐associated severe lung injury were observed when gemcitabine was combined with other therapies known to also cause lung injury. Physicians should have a high index of suspicion for this toxicity and report the relevant clinical findings to the FDA's AERS. Cancer 2006. © 2006 American Cancer Society." @default.
• W1517871387 created "2016-06-24" @default.
• W1517871387 creator A5003177689 @default.
• W1517871387 creator A5037145725 @default.
• W1517871387 creator A5037456539 @default.
• W1517871387 creator A5045928822 @default.
• W1517871387 creator A5063813993 @default.
• W1517871387 creator A5071586004 @default.
• W1517871387 creator A5089700881 @default.
• W1517871387 date "2006-03-27" @default.
• W1517871387 modified "2023-10-18" @default.
• W1517871387 title "Clinical features and correlates of gemcitabine-associated lung injury" @default.
• W1517871387 cites W1510527226 @default.
• W1517871387 cites W1575845701 @default.
• W1517871387 cites W1939916640 @default.
• W1517871387 cites W1958537456 @default.
• W1517871387 cites W1965860842 @default.
• W1517871387 cites W1969869755 @default.
• W1517871387 cites W1972787599 @default.
• W1517871387 cites W1981673039 @default.
• W1517871387 cites W1983706517 @default.
• W1517871387 cites W1990656227 @default.
• W1517871387 cites W1996978549 @default.
• W1517871387 cites W1996996208 @default.
• W1517871387 cites W1998484959 @default.
• W1517871387 cites W2007415320 @default.
• W1517871387 cites W2012882585 @default.
• W1517871387 cites W2021374170 @default.
• W1517871387 cites W2021702354 @default.
• W1517871387 cites W2030208002 @default.
• W1517871387 cites W2031889731 @default.
• W1517871387 cites W2049315983 @default.
• W1517871387 cites W2052942483 @default.
• W1517871387 cites W2054970421 @default.
• W1517871387 cites W2058058761 @default.
• W1517871387 cites W2060985892 @default.
• W1517871387 cites W2063497800 @default.
• W1517871387 cites W2064637847 @default.
• W1517871387 cites W2068454540 @default.
• W1517871387 cites W2074454702 @default.
• W1517871387 cites W2087565560 @default.
• W1517871387 cites W2092889324 @default.
• W1517871387 cites W2093369445 @default.
• W1517871387 cites W2128069079 @default.
• W1517871387 cites W2129481644 @default.
• W1517871387 cites W2134054382 @default.
• W1517871387 cites W2146341979 @default.
• W1517871387 cites W2147462699 @default.
• W1517871387 cites W2150908152 @default.
• W1517871387 cites W2157610459 @default.
• W1517871387 cites W2315587357 @default.
• W1517871387 cites W2317139162 @default.
• W1517871387 cites W2318815691 @default.
• W1517871387 cites W2331192179 @default.
• W1517871387 cites W2338638341 @default.
• W1517871387 cites W4240717991 @default.
• W1517871387 cites W88816475 @default.
• W1517871387 doi "https://doi.org/10.1002/cncr.21808" @default.
• W1517871387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16568459" @default.
• W1517871387 hasPublicationYear "2006" @default.
• W1517871387 type Work @default.
• W1517871387 sameAs 1517871387 @default.
• W1517871387 citedByCount "55" @default.
• W1517871387 countsByYear W15178713872012 @default.
• W1517871387 countsByYear W15178713872013 @default.
• W1517871387 countsByYear W15178713872014 @default.
• W1517871387 countsByYear W15178713872015 @default.
• W1517871387 countsByYear W15178713872016 @default.
• W1517871387 countsByYear W15178713872017 @default.
• W1517871387 countsByYear W15178713872018 @default.
• W1517871387 countsByYear W15178713872019 @default.
• W1517871387 countsByYear W15178713872020 @default.
• W1517871387 countsByYear W15178713872022 @default.
• W1517871387 countsByYear W15178713872023 @default.
• W1517871387 crossrefType "journal-article" @default.
• W1517871387 hasAuthorship W1517871387A5003177689 @default.
• W1517871387 hasAuthorship W1517871387A5037145725 @default.
• W1517871387 hasAuthorship W1517871387A5037456539 @default.
• W1517871387 hasAuthorship W1517871387A5045928822 @default.
• W1517871387 hasAuthorship W1517871387A5063813993 @default.
• W1517871387 hasAuthorship W1517871387A5071586004 @default.
• W1517871387 hasAuthorship W1517871387A5089700881 @default.
• W1517871387 hasConcept C126322002 @default.
• W1517871387 hasConcept C143998085 @default.
• W1517871387 hasConcept C197934379 @default.
• W1517871387 hasConcept C2776256026 @default.
• W1517871387 hasConcept C2776694085 @default.
• W1517871387 hasConcept C2780258809 @default.
• W1517871387 hasConcept C2781190966 @default.
• W1517871387 hasConcept C2781413609 @default.
• W1517871387 hasConcept C535046627 @default.
• W1517871387 hasConcept C71924100 @default.
• W1517871387 hasConceptScore W1517871387C126322002 @default.
• W1517871387 hasConceptScore W1517871387C143998085 @default.
• W1517871387 hasConceptScore W1517871387C197934379 @default.
• W1517871387 hasConceptScore W1517871387C2776256026 @default.
• W1517871387 hasConceptScore W1517871387C2776694085 @default.
• W1517871387 hasConceptScore W1517871387C2780258809 @default.

• next